Extract
ArQule Summarizes Abstracts Presented At AACR.
Pre-clinical findings support c-Met inhibition and activation of DNA damage response mechanisms as novel approaches to treating cancer
WOBURN, Mass. -- ArQule, Inc. (NASDAQ: ARQL) today announced that eleven abstracts submitted by the Company were presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), April 14-18, 2007 in Los Angeles. The AACR abstracts are based ...See the full content of this document
Sponsored links
